Southern Cross Health Insurance is reviewing claims related to ADHD and autism treatment after determining the conditions fall outside its mental health exclusion under a revised diagnostic classification review.
The reassessment follows feedback from clinicians, members and other health sector stakeholders about how earlier guidance to healthcare providers was being interpreted in practice. The insurer had issued correspondence to paediatricians in November explaining how existing policy wording should be applied to attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).
Regan Savage, chief sales and marketing officer for Southern Cross Health Insurance, said the company initiated a review after the guidance prompted uncertainty among providers.
"That feedback informed a more detailed review to ensure our guidance is clear, consistent and aligned with both clinical understanding and our policies," he said.
Savage added that the insurer is examining claims that may have been affected while the earlier interpretation was in place.
"We appreciate the constructive engagement with our members and specialists that helped inform this review, and we are currently reviewing any claims that may have been affected,” he said.
Earlier guidance had stated that ADHD and autism fell under mental health exclusions within the insurer’s policies. According to reporting by Radio New Zealand, some families said the interpretation meant treatment linked to the conditions was not funded.
Southern Cross had previously described the communication to clinicians as a clarification of existing policy rather than a change to coverage. At the time, the insurer said consultations related to the assessment of ADHD or ASD could be funded before a formal diagnosis, subject to policy terms. Once a diagnosis was confirmed, further consultations, assessments and related treatment were not covered under that interpretation.
Following the review, the insurer said ADHD and autism are classified as neurodevelopmental conditions rather than mental health conditions. On that basis, the mental health exclusion does not apply.
The earlier communication to paediatricians had been prompted by requests from providers seeking certainty on which post-diagnostic services could be billed to the insurer. A Wellington paediatrician told families his practice had been advised that the insurer classified ADHD and ASD as mental health disorders, a view the clinician said he did not share.
The issue surfaced at a time when families often seek private assessment because of constraints in public services. Reporting by RNZ noted long waiting lists for both public and private diagnostic pathways, prompting some families to pursue private consultations to obtain an assessment and support.
Advocacy group ADHD New Zealand has also called for greater public funding for diagnosis and treatment, stating that private health insurance is not accessible to many people living with ADHD.
Policy boundaries for neurodevelopmental and mental health conditions have drawn attention across the sector, particularly where insurance products are designed primarily for acute or unexpected health events rather than ongoing care needs.
Industry observers note that ADHD and autism can involve long-term management that includes medication, therapy and specialist support. This pattern of care raises questions for insurers about where to set limits between episodic medical treatment and long-duration conditions within private health policies.
Recent regulatory changes may also affect service demand. From February 2026, general practitioners and nurse practitioners in New Zealand will be able to diagnose ADHD and initiate treatment for adults, expanding access beyond paediatricians and psychiatrists.
Research cited in public reporting indicates that about 3% of New Zealanders aged five and over have been diagnosed with ADHD, while autism diagnoses affect around 2% of the population. Analysts have also pointed to gaps between estimated ADHD prevalence and the number of people receiving medication.
Within that context, Southern Cross’ review and its decision to reassess claims linked to ADHD and autism treatment form part of a wider discussion in the insurance market about how policy wording, clinical classification and long-term care needs intersect.
